CN116715576A - Method for synthesizing alpha-bromoaryl acetic acid compound - Google Patents
Method for synthesizing alpha-bromoaryl acetic acid compound Download PDFInfo
- Publication number
- CN116715576A CN116715576A CN202310608801.5A CN202310608801A CN116715576A CN 116715576 A CN116715576 A CN 116715576A CN 202310608801 A CN202310608801 A CN 202310608801A CN 116715576 A CN116715576 A CN 116715576A
- Authority
- CN
- China
- Prior art keywords
- reaction
- preparation
- acetic acid
- bromoaryl
- aryl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- -1 acetic acid compound Chemical class 0.000 title claims abstract description 15
- 238000000034 method Methods 0.000 title claims abstract description 13
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Natural products CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 title claims description 22
- 230000002194 synthesizing effect Effects 0.000 title abstract description 8
- 238000006243 chemical reaction Methods 0.000 claims abstract description 59
- 239000003054 catalyst Substances 0.000 claims abstract description 7
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims abstract description 6
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims abstract description 6
- 229910052794 bromium Inorganic materials 0.000 claims abstract description 6
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 30
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 26
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 20
- 238000004440 column chromatography Methods 0.000 claims description 11
- GQHTUMJGOHRCHB-UHFFFAOYSA-N 2,3,4,6,7,8,9,10-octahydropyrimido[1,2-a]azepine Chemical compound C1CCCCN2CCCN=C21 GQHTUMJGOHRCHB-UHFFFAOYSA-N 0.000 claims description 10
- 230000032050 esterification Effects 0.000 claims description 10
- 238000005886 esterification reaction Methods 0.000 claims description 10
- 229910052757 nitrogen Inorganic materials 0.000 claims description 10
- 239000003208 petroleum Substances 0.000 claims description 10
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 6
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 claims description 6
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 6
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 claims description 4
- LCGLNKUTAGEVQW-UHFFFAOYSA-N Dimethyl ether Chemical compound COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 claims description 4
- PCLIMKBDDGJMGD-UHFFFAOYSA-N N-bromosuccinimide Chemical compound BrN1C(=O)CCC1=O PCLIMKBDDGJMGD-UHFFFAOYSA-N 0.000 claims description 4
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims description 4
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 claims description 4
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 4
- 125000000217 alkyl group Chemical group 0.000 claims description 4
- 125000003118 aryl group Chemical group 0.000 claims description 4
- WLJVXDMOQOGPHL-UHFFFAOYSA-N phenylacetic acid Chemical compound OC(=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-UHFFFAOYSA-N 0.000 claims description 4
- HXITXNWTGFUOAU-UHFFFAOYSA-N phenylboronic acid Chemical compound OB(O)C1=CC=CC=C1 HXITXNWTGFUOAU-UHFFFAOYSA-N 0.000 claims description 4
- 239000002904 solvent Substances 0.000 claims description 4
- 125000003107 substituted aryl group Chemical group 0.000 claims description 4
- 239000002253 acid Substances 0.000 claims description 3
- 239000003513 alkali Substances 0.000 claims description 3
- 238000001308 synthesis method Methods 0.000 claims description 3
- VASOMTXTRMYSKD-UHFFFAOYSA-N (2,3,4,5,6-pentafluorophenyl)boronic acid Chemical compound OB(O)C1=C(F)C(F)=C(F)C(F)=C1F VASOMTXTRMYSKD-UHFFFAOYSA-N 0.000 claims description 2
- KYVBNYUBXIEUFW-UHFFFAOYSA-N 1,1,3,3-tetramethylguanidine Chemical compound CN(C)C(=N)N(C)C KYVBNYUBXIEUFW-UHFFFAOYSA-N 0.000 claims description 2
- XEKTVXADUPBFOA-UHFFFAOYSA-N 1-bromo-2,3,4,5,6-pentafluorobenzene Chemical compound FC1=C(F)C(F)=C(Br)C(F)=C1F XEKTVXADUPBFOA-UHFFFAOYSA-N 0.000 claims description 2
- MENYRYNFSIBDQN-UHFFFAOYSA-N 5,5-dibromoimidazolidine-2,4-dione Chemical compound BrC1(Br)NC(=O)NC1=O MENYRYNFSIBDQN-UHFFFAOYSA-N 0.000 claims description 2
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 claims description 2
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 claims description 2
- 239000002879 Lewis base Substances 0.000 claims description 2
- 125000003545 alkoxy group Chemical group 0.000 claims description 2
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 claims description 2
- 239000004327 boric acid Substances 0.000 claims description 2
- 238000001311 chemical methods and process Methods 0.000 claims description 2
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 2
- 238000001035 drying Methods 0.000 claims description 2
- 125000005843 halogen group Chemical group 0.000 claims description 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 2
- 150000007527 lewis bases Chemical class 0.000 claims description 2
- 239000012046 mixed solvent Substances 0.000 claims description 2
- 125000001624 naphthyl group Chemical group 0.000 claims description 2
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims description 2
- ZPATUOFYXSBHMN-UHFFFAOYSA-N pyridine;trihydrobromide Chemical compound [H+].[H+].[H+].[Br-].[Br-].[Br-].C1=CC=NC=C1 ZPATUOFYXSBHMN-UHFFFAOYSA-N 0.000 claims description 2
- 230000035484 reaction time Effects 0.000 claims description 2
- 229910000029 sodium carbonate Inorganic materials 0.000 claims description 2
- 238000003756 stirring Methods 0.000 claims description 2
- 125000001424 substituent group Chemical group 0.000 claims description 2
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims description 2
- 238000002360 preparation method Methods 0.000 claims 7
- MARXMDRWROUXMD-UHFFFAOYSA-N 2-bromoisoindole-1,3-dione Chemical compound C1=CC=C2C(=O)N(Br)C(=O)C2=C1 MARXMDRWROUXMD-UHFFFAOYSA-N 0.000 claims 1
- 239000002585 base Substances 0.000 claims 1
- IPWKHHSGDUIRAH-UHFFFAOYSA-N bis(pinacolato)diboron Chemical compound O1C(C)(C)C(C)(C)OB1B1OC(C)(C)C(C)(C)O1 IPWKHHSGDUIRAH-UHFFFAOYSA-N 0.000 claims 1
- 125000000218 acetic acid group Chemical class C(C)(=O)* 0.000 abstract description 3
- 239000000758 substrate Substances 0.000 abstract description 2
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 24
- XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 16
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 16
- 238000010586 diagram Methods 0.000 description 14
- 238000000926 separation method Methods 0.000 description 9
- 238000001460 carbon-13 nuclear magnetic resonance spectrum Methods 0.000 description 8
- 239000000203 mixture Substances 0.000 description 8
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 8
- 238000000746 purification Methods 0.000 description 8
- 238000003786 synthesis reaction Methods 0.000 description 8
- 230000015572 biosynthetic process Effects 0.000 description 5
- 150000001875 compounds Chemical class 0.000 description 5
- 230000000975 bioactive effect Effects 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 150000001242 acetic acid derivatives Chemical class 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 229960002390 flurbiprofen Drugs 0.000 description 2
- SYTBZMRGLBWNTM-UHFFFAOYSA-N flurbiprofen Chemical compound FC1=CC(C(C(O)=O)C)=CC=C1C1=CC=CC=C1 SYTBZMRGLBWNTM-UHFFFAOYSA-N 0.000 description 2
- HBENZIXOGRCSQN-VQWWACLZSA-N (1S,2S,6R,14R,15R,16R)-5-(cyclopropylmethyl)-16-[(2S)-2-hydroxy-3,3-dimethylpentan-2-yl]-15-methoxy-13-oxa-5-azahexacyclo[13.2.2.12,8.01,6.02,14.012,20]icosa-8(20),9,11-trien-11-ol Chemical compound N1([C@@H]2CC=3C4=C(C(=CC=3)O)O[C@H]3[C@@]5(OC)CC[C@@]2([C@@]43CC1)C[C@@H]5[C@](C)(O)C(C)(C)CC)CC1CC1 HBENZIXOGRCSQN-VQWWACLZSA-N 0.000 description 1
- FANCTJAFZSYTIS-IQUVVAJASA-N (1r,3s,5z)-5-[(2e)-2-[(1r,3as,7ar)-7a-methyl-1-[(2r)-4-(phenylsulfonimidoyl)butan-2-yl]-2,3,3a,5,6,7-hexahydro-1h-inden-4-ylidene]ethylidene]-4-methylidenecyclohexane-1,3-diol Chemical compound C([C@@H](C)[C@@H]1[C@]2(CCCC(/[C@@H]2CC1)=C\C=C\1C([C@@H](O)C[C@H](O)C/1)=C)C)CS(=N)(=O)C1=CC=CC=C1 FANCTJAFZSYTIS-IQUVVAJASA-N 0.000 description 1
- PHDIJLFSKNMCMI-ITGJKDDRSA-N (3R,4S,5R,6R)-6-(hydroxymethyl)-4-(8-quinolin-6-yloxyoctoxy)oxane-2,3,5-triol Chemical compound OC[C@@H]1[C@H]([C@@H]([C@H](C(O1)O)O)OCCCCCCCCOC=1C=C2C=CC=NC2=CC=1)O PHDIJLFSKNMCMI-ITGJKDDRSA-N 0.000 description 1
- MNIPVWXWSPXERA-IDNZQHFXSA-N (6r,7r)-1-[(4s,5r)-4-acetyloxy-5-methyl-3-methylidene-6-phenylhexyl]-4,7-dihydroxy-6-(11-phenoxyundecanoyloxy)-2,8-dioxabicyclo[3.2.1]octane-3,4,5-tricarboxylic acid Chemical compound C([C@@H](C)[C@H](OC(C)=O)C(=C)CCC12[C@@H]([C@@H](OC(=O)CCCCCCCCCCOC=3C=CC=CC=3)C(O1)(C(O)=O)C(O)(C(O2)C(O)=O)C(O)=O)O)C1=CC=CC=C1 MNIPVWXWSPXERA-IDNZQHFXSA-N 0.000 description 1
- JNPGUXGVLNJQSQ-BGGMYYEUSA-M (e,3r,5s)-7-[4-(4-fluorophenyl)-1,2-di(propan-2-yl)pyrrol-3-yl]-3,5-dihydroxyhept-6-enoate Chemical compound CC(C)N1C(C(C)C)=C(\C=C\[C@@H](O)C[C@@H](O)CC([O-])=O)C(C=2C=CC(F)=CC=2)=C1 JNPGUXGVLNJQSQ-BGGMYYEUSA-M 0.000 description 1
- VAVHMEQFYYBAPR-ITWZMISCSA-N (e,3r,5s)-7-[4-(4-fluorophenyl)-1-phenyl-2-propan-2-ylpyrrol-3-yl]-3,5-dihydroxyhept-6-enoic acid Chemical compound CC(C)C1=C(\C=C\[C@@H](O)C[C@@H](O)CC(O)=O)C(C=2C=CC(F)=CC=2)=CN1C1=CC=CC=C1 VAVHMEQFYYBAPR-ITWZMISCSA-N 0.000 description 1
- HMUNWXXNJPVALC-UHFFFAOYSA-N 1-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperazin-1-yl]-2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)N1CCN(CC1)C(CN1CC2=C(CC1)NN=N2)=O HMUNWXXNJPVALC-UHFFFAOYSA-N 0.000 description 1
- VZSRBBMJRBPUNF-UHFFFAOYSA-N 2-(2,3-dihydro-1H-inden-2-ylamino)-N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]pyrimidine-5-carboxamide Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C(=O)NCCC(N1CC2=C(CC1)NN=N2)=O VZSRBBMJRBPUNF-UHFFFAOYSA-N 0.000 description 1
- IIEJGTQVBJHMDL-UHFFFAOYSA-N 2-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]-5-[2-oxo-2-[3-(sulfamoylamino)pyrrolidin-1-yl]ethyl]-1,3,4-oxadiazole Chemical compound C1CN(CC1NS(=O)(=O)N)C(=O)CC2=NN=C(O2)C3=CN=C(N=C3)NC4CC5=CC=CC=C5C4 IIEJGTQVBJHMDL-UHFFFAOYSA-N 0.000 description 1
- SXAMGRAIZSSWIH-UHFFFAOYSA-N 2-[3-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]-1,2,4-oxadiazol-5-yl]-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C1=NOC(=N1)CC(=O)N1CC2=C(CC1)NN=N2 SXAMGRAIZSSWIH-UHFFFAOYSA-N 0.000 description 1
- WZFUQSJFWNHZHM-UHFFFAOYSA-N 2-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperazin-1-yl]-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)N1CCN(CC1)CC(=O)N1CC2=C(CC1)NN=N2 WZFUQSJFWNHZHM-UHFFFAOYSA-N 0.000 description 1
- ZRPAUEVGEGEPFQ-UHFFFAOYSA-N 2-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]pyrazol-1-yl]-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C=1C=NN(C=1)CC(=O)N1CC2=C(CC1)NN=N2 ZRPAUEVGEGEPFQ-UHFFFAOYSA-N 0.000 description 1
- YJLUBHOZZTYQIP-UHFFFAOYSA-N 2-[5-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]-1,3,4-oxadiazol-2-yl]-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C1=NN=C(O1)CC(=O)N1CC2=C(CC1)NN=N2 YJLUBHOZZTYQIP-UHFFFAOYSA-N 0.000 description 1
- QLVGHFBUSGYCCG-UHFFFAOYSA-N 2-amino-n-(1-cyano-2-phenylethyl)acetamide Chemical compound NCC(=O)NC(C#N)CC1=CC=CC=C1 QLVGHFBUSGYCCG-UHFFFAOYSA-N 0.000 description 1
- HIHOEGPXVVKJPP-JTQLQIEISA-N 5-fluoro-2-[[(1s)-1-(5-fluoropyridin-2-yl)ethyl]amino]-6-[(5-methyl-1h-pyrazol-3-yl)amino]pyridine-3-carbonitrile Chemical compound N([C@@H](C)C=1N=CC(F)=CC=1)C(C(=CC=1F)C#N)=NC=1NC=1C=C(C)NN=1 HIHOEGPXVVKJPP-JTQLQIEISA-N 0.000 description 1
- CONKBQPVFMXDOV-QHCPKHFHSA-N 6-[(5S)-5-[[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperazin-1-yl]methyl]-2-oxo-1,3-oxazolidin-3-yl]-3H-1,3-benzoxazol-2-one Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)N1CCN(CC1)C[C@H]1CN(C(O1)=O)C1=CC2=C(NC(O2)=O)C=C1 CONKBQPVFMXDOV-QHCPKHFHSA-N 0.000 description 1
- 229940126650 Compound 3f Drugs 0.000 description 1
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 1
- PHSPJQZRQAJPPF-UHFFFAOYSA-N N-alpha-Methylhistamine Chemical compound CNCCC1=CN=CN1 PHSPJQZRQAJPPF-UHFFFAOYSA-N 0.000 description 1
- CMWTZPSULFXXJA-UHFFFAOYSA-N Naproxen Natural products C1=C(C(C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-UHFFFAOYSA-N 0.000 description 1
- 208000004550 Postoperative Pain Diseases 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 150000003980 alpha-chlorocarboxylic acids Chemical class 0.000 description 1
- 229940124599 anti-inflammatory drug Drugs 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- OSVHLUXLWQLPIY-KBAYOESNSA-N butyl 2-[(6aR,9R,10aR)-1-hydroxy-9-(hydroxymethyl)-6,6-dimethyl-6a,7,8,9,10,10a-hexahydrobenzo[c]chromen-3-yl]-2-methylpropanoate Chemical compound C(CCC)OC(C(C)(C)C1=CC(=C2[C@H]3[C@H](C(OC2=C1)(C)C)CC[C@H](C3)CO)O)=O OSVHLUXLWQLPIY-KBAYOESNSA-N 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 229940125796 compound 3d Drugs 0.000 description 1
- 238000001212 derivatisation Methods 0.000 description 1
- ZOCHARZZJNPSEU-UHFFFAOYSA-N diboron Chemical compound B#B ZOCHARZZJNPSEU-UHFFFAOYSA-N 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000000806 fluorine-19 nuclear magnetic resonance spectrum Methods 0.000 description 1
- 229960001680 ibuprofen Drugs 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 239000000543 intermediate Substances 0.000 description 1
- MUTCAPXLKRYEPR-ITWZMISCSA-N methyl (e,3r,5s)-7-[4-bromo-2,3-bis(4-fluorophenyl)-5-propan-2-ylpyrrol-1-yl]-3,5-dihydroxyhept-6-enoate Chemical compound COC(=O)C[C@H](O)C[C@H](O)\C=C\N1C(C(C)C)=C(Br)C(C=2C=CC(F)=CC=2)=C1C1=CC=C(F)C=C1 MUTCAPXLKRYEPR-ITWZMISCSA-N 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- GVOISEJVFFIGQE-YCZSINBZSA-N n-[(1r,2s,5r)-5-[methyl(propan-2-yl)amino]-2-[(3s)-2-oxo-3-[[6-(trifluoromethyl)quinazolin-4-yl]amino]pyrrolidin-1-yl]cyclohexyl]acetamide Chemical compound CC(=O)N[C@@H]1C[C@H](N(C)C(C)C)CC[C@@H]1N1C(=O)[C@@H](NC=2C3=CC(=CC=C3N=CN=2)C(F)(F)F)CC1 GVOISEJVFFIGQE-YCZSINBZSA-N 0.000 description 1
- 229960002009 naproxen Drugs 0.000 description 1
- CMWTZPSULFXXJA-VIFPVBQESA-N naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C67/00—Preparation of carboxylic acid esters
- C07C67/08—Preparation of carboxylic acid esters by reacting carboxylic acids or symmetrical anhydrides with the hydroxy or O-metal group of organic compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C51/00—Preparation of carboxylic acids or their salts, halides or anhydrides
- C07C51/347—Preparation of carboxylic acids or their salts, halides or anhydrides by reactions not involving formation of carboxyl groups
- C07C51/363—Preparation of carboxylic acids or their salts, halides or anhydrides by reactions not involving formation of carboxyl groups by introduction of halogen; by substitution of halogen atoms by other halogen atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
The invention discloses a method for synthesizing alpha-bromoaryl acetic acid compounds based on aryl acetic acid compounds, belonging to the field of organic chemistry. The method takes aryl acetic acid compounds and bromine sources as substrates, and synthesizes a series of alpha-bromoaryl acetic acid compounds through two-component reaction under the conditions of catalyst, alkalinity and 40 ℃.
Description
Technical Field
The invention belongs to the technical field of organic synthesis, and particularly relates to a method for synthesizing alpha-bromoaryl acetic acid compounds based on aryl acetic acid compounds.
Background
Alpha-bromo carboxylic acids are key building blocks for many bioactive substances and are also synthetic intermediates for a variety of drug molecules. In the field of pharmaceutical synthesis, α -bromocarboxylic acid can be converted into anti-inflammatory drugs such as ibuprofen, naproxen, flurbiprofen, etc. by a simple derivatization reaction (angelw, chem, int, ed. 2019, 58, 11355). In addition, flurbiprofen (otolyng. Head. Neg. 2016, 155, 166), a drug for the clinical treatment of postoperative pain, can also be synthesized by α -bromocarboxylic acid.
Because of the p-pi conjugated effect of carboxyl in carboxylic acid molecule, the electropositivity of carboxyl carbon is weakened, and the synthesis of alpha-bromo carboxylic acid compound by a universal method is difficult. In this context, existing methods for synthesizing α -bromocarboxylic acids are as follows: synthesizing alpha-bromocarboxylic acid (Ber, dtsch, chem, ges, 1881, 14, 891.) by substituting acetic acid compounds and bromine simple substance under the action of catalytic amount of phosphorus tribromide; the synthesis of alpha-bromocarboxylic acid by direct heat refluxing of alpha-chlorocarboxylic acid with elemental bromine (j. Hetercycl. Chem. 2001, 38, 997). The synthesis method has the advantages of intense reaction and high synthesis difficulty. Therefore, the invention has important research value in an economical and practical synthesis method of the alpha-bromo-carboxylic acid.
Disclosure of Invention
The alpha-bromoaryl acetic acid compound synthesized by the invention is not only a core skeleton of a plurality of bioactive molecules, but also an important synthon in organic synthesis. Therefore, the type of the novel alpha-bromoaryl acetic acid compound is expanded, and the realization of the efficient synthesis of bioactive molecules has important research significance.
In order to achieve the above object, the present invention provides a method for synthesizing an α -bromoaryl acetic acid compound having a structure represented by formula i:
。
wherein Ar is selected from any one of aryl, naphthyl, benzyl, substituted benzyl and substituted aryl.
R 1 Selected from any one of saturated alkyl groups and hydrogen atoms.
The substituent of the substituted aryl and the substituted benzyl is any one of saturated alkyl, halogen atom, cyano, alkoxy, aryl and trifluoro sulfonic acid.
The method comprises the following steps: under the protection of nitrogen, sequentially adding 2-phenylacetic acid, a bromine source, a catalyst, alkali and a solvent into a drying reactor, and stirring at a certain temperature until the reaction is completed to obtain an alpha-bromoaryl acetic acid compound, wherein the chemical process is shown as a reaction formula II:
。
the [ Br ] is selected from any different one of bromine simple substance, dibromohydantoin, tribromide pyridine, pentafluorobromobenzene, N-bromosuccinimide, N-bromoo-sulfonylbenzene imide and dibromomeldonium acid.
The alkali is selected from any different one of 4-dimethylaminopyridine, pyridine, tetramethylguanidine, 1, 8-diazabicyclo (5.4.0) undec-7-ene and sodium carbonate.
The solvent is selected from any different one of toluene, acetonitrile, diethyl ether, dimethyl ether and tetrahydrofuran.
The catalyst is selected from any one of phenylboronic acid, boric acid, pentafluorophenylboronic acid, dipyrniol diboron and tetraacetyl diboronate.
The molar ratio of the aryl acetic acid compound to the bromine source to the Lewis base to the catalyst is 1.0: (1.0-1.5): (2.0-2.5): 0.2.
the reaction time is 24-72h.
The reaction temperature is 25-100 ℃.
After the reaction, the esterification operation is carried out, and the column chromatography separation is carried out by using the mixed solvent of petroleum ether and ethyl acetate.
The beneficial effects of the invention are as follows: the invention provides a method for synthesizing an alpha-bromoaryl acetic acid compound, which is scientific and reasonable and has the advantages of high yield, wide substrate application range, simple operation, convenient post-treatment and the like.
Drawings
FIG. 1 is a schematic diagram of example 1 1 H NMR spectrum; FIG. 2 is a schematic diagram of example 1 13 C NMR spectrum; FIG. 3 is a schematic diagram of example 1 19 F NMR spectrum.
FIG. 4 is a schematic diagram of example 2 1 H NMR spectrum; FIG. 5 is a schematic diagram of example 2 13 C NMR spectrum.
FIG. 6 is a diagram of example 3 1 H NMR spectrum; FIG. 7 is a diagram of example 3 13 C NMR spectrum.
FIG. 8 is a schematic diagram of example 4 1 H NMR spectrum; FIG. 9 is a diagram of example 4 13 C NMR spectrum.
FIG. 10 is a diagram of example 5 1 H NMR spectrum; FIG. 11 is a diagram of example 5 13 C NMR spectrum.
FIG. 12 is a schematic illustration of example 6 1 H NMR spectrum; FIG. 13 is a schematic illustration of example 6 13 C NMR spectrum.
FIG. 14 is a schematic diagram of example 7 1 H NMR spectrum; FIG. 15 is a schematic view of example 7 13 C NMR spectrum.
FIG. 16 is a diagram of example 8 1 H NMR spectrum; FIG. 17 is a diagram of example 8 13 C NMR spectrum.
Detailed Description
The method of the present invention is described herein by way of specific examples, but the present invention is not limited thereto, and any modification, equivalent substitution, improvement, etc. within the scope of the technical idea of the present invention should be included in the scope of the present invention.
Example 1:
the reaction equation is as follows:
。
under nitrogen, compound 1a (0.1 mmol), 2a (0.15 mmol) and tetraacetyl diboronate (20 mol%) were added to a dry reactor and 1, 8-diazabicyclo (5.4.0) undec-7-ene (2.0 eq) and ethylene glycol dimethyl ether (1.0 mL) were added and stirred at 25 ℃ until the reaction was complete. After completion of the reaction, the reaction solution was concentrated by a rotary evaporator to obtain 3a. In order to facilitate the subsequent separation and purification, the product is subjected to esterification operation. Compound 3a (0.1 mmol) was added to the dried reactor and thionyl chloride (2.0 eq) and methanol (1.0 mL) were added and stirred at 80 ℃ until the reaction was complete. After the reaction was completed, the mixture was separated by column chromatography using petroleum ether and ethyl acetate 80:1 to give pure 3aa in 51% yield.
The nuclear magnetic data of 3aa are as follows:
1 H NMR (600 MHz, CDCl 3 ) δ 7.49 (m, 2H), 7.13 – 7.00 (m, 2H), 5.34 (s, 1H), 3.78 (s, 3H).。
13 C NMR (151 MHz, CDCl 3 ) δ 168.73 , 131.64 , 129.96 , 115.85 , 58.10 , 53.43 .。
19 F NMR (565 MHz, CDCl 3 ) δ -111.67.。
example 2:
the reaction equation is as follows:
。
compound 1b (0.1 mmol), 2a (0.15 mmol) and tetraacetyl diboronate (20 mol%) were added to a dry reactor under nitrogen, followed by 1, 8-diazabicyclo (5.4.0) undec-7-ene (2.0 eq) and ethylene glycol dimethyl ether (1.0 mL) and stirred at 25℃until the reaction was completed. After completion of the reaction, the reaction solution was concentrated by a rotary evaporator to obtain 3b. In order to facilitate the subsequent separation and purification, the product is subjected to esterification operation. Compound 3b (0.1 mmol) was added to the dried reactor and thionyl chloride (2.0 eq) and methanol (1.0 mL) were added and stirred at 80 ℃ until the reaction was complete. After completion of the reaction, the mixture was separated by column chromatography using petroleum ether and ethyl acetate at 80:1 to give pure 3ba in 54% yield.
The nuclear magnetic data of 3ba are as follows:
1 H NMR (600 MHz, CDCl 3 ) δ 7.44 (d, J = 8.5 Hz, 2H), 7.36 (d, J = 8.5 Hz, 2H), 5.33 (s, 1H), 3.78 (s, 3H).。
13 C NMR (151 MHz, CDCl 3 ) δ 168.53, 135.42, 134.21, 129.36, 129.12, 58.10, 53.48.。
example 3:
the reaction equation is as follows:
。
compound 1c (0.1 mmol), 2a (0.15 mmol) and tetraacetyl diboronate (20 mol%) were added to a dry reactor under nitrogen, followed by 1, 8-diazabicyclo (5.4.0) undec-7-ene (2.0 eq) and ethylene glycol dimethyl ether (1.0 mL) and stirred at 25℃until the reaction was completed. After completion of the reaction, the reaction solution was concentrated by a rotary evaporator to obtain 3c. In order to facilitate the subsequent separation and purification, the product is subjected to esterification operation. Compound 3c (0.1 mmol) was added to the dried reactor and thionyl chloride (2.0 eq) and methanol (1.0 mL) were added and stirred at 80 ℃ until the reaction was complete. After the reaction was completed, the mixture was separated by column chromatography using petroleum ether and ethyl acetate at 80:1 to give pure 3ca in 49% yield.
The nuclear magnetic data of 3ca are as follows:
1 H NMR (600 MHz, CDCl 3 ) δ 7.54 – 7.50 (m, 2H), 7.40 – 7.35 (m, 2H), 5.31 (s, 1H), 3.78 (s, 3H).。
13 C NMR (151 MHz, CDCl 3 ) δ 168.45, 134.72, 132.08, 129.63, 123.62, 58.15, 53.49.。
example 4:
the reaction equation is as follows:
。
compound 1d (0.1 mmol), 2a (0.15 mmol) and tetraacetyl diboronate (20 mol%) were added to a dry reactor under nitrogen, followed by 1, 8-diazabicyclo (5.4.0) undec-7-ene (2.0 eq) and ethylene glycol dimethyl ether (1.0 mL) and stirred at 25℃until the reaction was completed. After completion of the reaction, the reaction solution was concentrated by a rotary evaporator to obtain 3d. In order to facilitate the subsequent separation and purification, the product is subjected to esterification operation. Compound 3d (0.1 mmol) was added to the dried reactor and thionyl chloride (2.0 eq) and methanol (1.0 mL) were added and stirred at 80 ℃ until the reaction was complete. After the reaction was completed, the mixture was separated by column chromatography using petroleum ether and ethyl acetate at 80:1 to give pure 3da in 46% yield.
The nuclear magnetic data of 3da are as follows:
1 H NMR (600 MHz, CDCl 3 ) δ 7.75 – 7.70 (m, 2H), 7.26 – 7.21 (m, 2H), 5.29 (s, 1H), 3.77 (s, 3H).。
13 C NMR (151 MHz, CDCl 3 ) δ 168.41, 138.03, 135.36, 129.72, 95.41, 58.26, 53.48.。
example 5:
the reaction equation is as follows:
。
compound 1e (0.1 mmol), 2a (0.15 mmol) and tetraacetyl diboronate (20 mol%) were added to a dry reactor under nitrogen protection, followed by 1, 8-diazabicyclo (5.4.0) undec-7-ene (2.0 eq) and ethylene glycol dimethyl ether (1.0 mL) and stirred at 25 ℃ until the reaction was completed. After completion of the reaction, the reaction solution was concentrated by a rotary evaporator to obtain 3e. In order to facilitate the subsequent separation and purification, the product is subjected to esterification operation. Compound 3e (0.1 mmol) was added to the dried reactor and thionyl chloride (2.0 eq) and methanol (1.0 mL) were added and stirred at 80 ℃ until the reaction was complete. After the reaction was completed, the mixture was separated by column chromatography using petroleum ether and ethyl acetate at 80:1 to give pure 3ea in 45% yield.
The nuclear magnetic data of 3ea are as follows:
1 H NMR (600 MHz, CDCl 3 ) δ 7.34 – 7.25 (m, 2H), 7.11 (d, J = 7.9 Hz, 2H), 5.26 (s, 1H), 3.69 (s, 3H), 2.28 (s, 3H).。
13 C NMR (151 MHz, CDCl 3 ) δ 169.01, 139.44, 132.84, 129.60, 127.87, 58.91, 53.30, 21.23.。
example 6:
the reaction equation is as follows:
。
under nitrogen, compound 1f (0.1 mmol), 2a (0.15 mmol) and tetraacetyl diboronate (20 mol%) were added to a dry reactor and 1, 8-diazabicyclo (5.4.0) undec-7-ene (2.0 eq) and ethylene glycol dimethyl ether (1.0 mL) were added and stirred at 25 ℃ until the reaction was complete. After completion of the reaction, the reaction solution was concentrated by a rotary evaporator to obtain 3f. In order to facilitate the subsequent separation and purification, the product is subjected to esterification operation. Compound 3f (0.1 mmol) was added to the dried reactor and thionyl chloride (2.0 eq) and methanol (1.0 mL) were added and stirred at 80 ℃ until the reaction was complete. After the reaction was completed, the mixture was separated by column chromatography using petroleum ether and ethyl acetate at 80:1 to give pure 3fa in 37% yield.
The nuclear magnetic data of 3fa are as follows:
1 H NMR (600 MHz, CDCl 3 ) δ 7.64 (m, 4H), 5.40 (s, 1H), 3.79 (s, 3H).。
13 C NMR (151 MHz, CDCl 3 ) δ 168.26, 139.46, 131.80, 131.58, 131.37, 131.15, 128.43, 125.92, 125.90, 125.87, 125.85, 124.63, 122.83, 58.01, 53.60.。
example 7:
the reaction equation is as follows:
。
1g (0.1 mmol), 2a (0.15 mmol) and tetraacetyl diboronate (20 mol%) of the compound are introduced into a dry reactor under nitrogen, 1, 8-diazabicyclo (5.4.0) undec-7-ene (2.0 eq) and ethylene glycol dimethyl ether (1.0 mL) are added and stirred at 25℃until the reaction is completed. After completion of the reaction, the reaction solution was concentrated by a rotary evaporator to obtain 3g. In order to facilitate the subsequent separation and purification, the product is subjected to esterification operation. 3g (0.1 mmol) of the compound was charged into a dry reactor, and thionyl chloride (2.0 eq) and methanol (1.0 mL) were added thereto and stirred at 80℃until the reaction was completed. After completion of the reaction, the mixture was separated by column chromatography using petroleum ether and ethyl acetate at 80:1 to give pure 3ga in 59% yield.
The nuclear magnetic data at 3ga were as follows:
1 H NMR (400 MHz, CDCl 3 ) δ 7.58 (m, 1H), 7.49 (m, 1H), 7.37 (m, 2H), 7.29 – 7.08 (m, 6H), 7.04 (m, 1H), 5.91 (d, J = 2.5 Hz, 1H), 5.32 – 5.17 (m, 4H), 3.71 (d, J = 2.6 Hz, 3H).。
13 C NMR (151 MHz, CDCl 3 ) δ 168.98, 151.48, 145.52, 135.11, 135.07, 134.10, 133.00, 132.82, 130.85, 129.85, 129.76, 129.45, 129.35, 129.31, 129.21, 129.16, 127.03, 126.90, 124.89, 124.84, 122.27, 121.21, 114.83, 114.78, 72.15, 68.15, 53.32, 53.17, 40.78.。
example 8:
the reaction equation is as follows:
。
under nitrogen, the compound 1h (0.1 mmol), 2a (0.15 mmol), tetraacetyl diboronate (20 mol%) was added to the dry reactor, followed by 1, 8-diazabicyclo (5.4.0) undec-7-ene (2.0 eq) and ethylene glycol dimethyl ether (1.0 mL) and stirred at 25 ℃ until the reaction was completed. After completion of the reaction, the reaction solution was concentrated by a rotary evaporator for 3 hours. In order to facilitate the subsequent separation and purification, the product is subjected to esterification operation. Compound 3h (0.1 mmol) was added to the dried reactor and thionyl chloride (2.0 eq) and methanol (1.0 mL) were added and stirred at 80 ℃ to the end of the reaction. After the reaction was completed, the mixture was separated by column chromatography using petroleum ether and ethyl acetate at 80:1 to give pure 3ha in 61% yield.
The nuclear magnetic data of 3ha are as follows:
1 H NMR (600 MHz, CDCl 3 ) δ 7.25 (d, J = 1.9 Hz, 1H), 7.20 (m, 1H), 7.13 (d, J = 7.9 Hz, 1H), 5.31 (s, 1H), 3.76 (s, 3H), 2.26 (d, J = 7.4 Hz, 6H).。
13 C NMR (151 MHz, CDCl 3 ) δ 169.09, 138.17, 137.37, 133.18, 130.13, 129.03, 125.37, 59.03, 53.30, 19.80, 19.59.。
from the above examples, it can be seen that the various and efficient syntheses of α -bromoaryl acetic acid compounds are possible according to the present invention.
Claims (12)
1. A synthesis method of an alpha-bromoaryl acetic acid compound comprises the following steps:
2. wherein Ar is selected from any one of aryl, naphthyl, benzyl, substituted benzyl and substituted aryl;
R 1 selected from any one of saturated alkyl groups and hydrogen atoms.
3. The substituent of the substituted aryl and the substituted benzyl is any one of saturated alkyl, halogen atom, cyano, alkoxy, aryl and trifluoro sulfonic acid.
4. The method comprises the following steps: under the protection of nitrogen, sequentially adding 2-phenylacetic acid, a bromine source, a catalyst, alkali and a solvent into a drying reactor, stirring at a certain temperature until the reaction is completed, and separating by column chromatography to obtain the alpha-bromoaryl acetic acid compound, wherein the chemical process is shown in a reaction formula II:
5. the preparation method according to claim 1, wherein [ Br ] is any different one selected from the group consisting of elemental bromine, dibromohydantoin, pyridine tribromide, pentafluorobromobenzene, N-bromosuccinimide, N-bromophthalimide, dibromomeldonium acid.
6. The preparation method according to claim 1, wherein the base is any different one selected from 4-dimethylaminopyridine, pyridine, tetramethylguanidine, 1, 8-diazabicyclo (5.4.0) undec-7-ene, and sodium carbonate.
7. The preparation method according to claim 1, wherein the solvent is selected from any different one of toluene, acetonitrile, diethyl ether, dimethyl ether, and tetrahydrofuran.
8. The preparation method according to claim 1, wherein the catalyst is any one selected from phenylboronic acid, boric acid, pentafluorophenylboronic acid, dipinacol diboron, and tetraacetyldiboronate.
9. The preparation method according to claim 1, wherein the molar ratio of the aryl acetic acid compound, [ Br ], the Lewis base and the catalyst is 1.0: (1.0-1.5): (2.0-2.5): 0.2.
10. the preparation method according to claim 1, wherein the reaction time is 24 to 72 hours.
11. The preparation method according to claim 1, wherein the reaction temperature is 25 to 100 ℃.
12. The process according to claim 1, wherein the esterification is carried out after the completion of the reaction, and the column chromatography is carried out using a mixed solvent of petroleum ether and ethyl acetate.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202310608801.5A CN116715576A (en) | 2023-05-29 | 2023-05-29 | Method for synthesizing alpha-bromoaryl acetic acid compound |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202310608801.5A CN116715576A (en) | 2023-05-29 | 2023-05-29 | Method for synthesizing alpha-bromoaryl acetic acid compound |
Publications (1)
Publication Number | Publication Date |
---|---|
CN116715576A true CN116715576A (en) | 2023-09-08 |
Family
ID=87872475
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202310608801.5A Pending CN116715576A (en) | 2023-05-29 | 2023-05-29 | Method for synthesizing alpha-bromoaryl acetic acid compound |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN116715576A (en) |
-
2023
- 2023-05-29 CN CN202310608801.5A patent/CN116715576A/en active Pending
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Zhou et al. | Geminal difunctionalization of α-diazo arylmethylphosphonates: synthesis of fluorinated phosphonates | |
CN108558692B (en) | Preparation method of amide compound | |
CN114634482B (en) | Diazonium difluoro methylation reagent and synthetic method and application thereof | |
CN111440166A (en) | Polysubstituted indolizine derivative and preparation method thereof | |
CN116715576A (en) | Method for synthesizing alpha-bromoaryl acetic acid compound | |
CN115010600B (en) | Method for synthesizing polyfluoroaryl carboxylic acid compound based on aryl fluorocarbon bond carboxylation reaction | |
CN113387886B (en) | 2-aminodibenzo [ c, e ] azepine compound and synthetic method thereof | |
CN113912562B (en) | Synthetic method of oxazepine derivative | |
CN110734354B (en) | Method for preparing biaryl compound from alcohol compound | |
CN111943874B (en) | Aryl naproxen derivative high-valence iodine compound and preparation method and application thereof | |
CN114478245A (en) | Asymmetric synthesis method of chiral gamma-alkynyl-alpha-keto acid ester compound | |
CN109574866B (en) | Preparation method of 2, 6-dimethylaniline long-chain compound | |
CN114106050B (en) | Compact chiral environment biphenanthrene skeleton chiral phosphoric acid and preparation method and application thereof | |
CN115353457B (en) | Asymmetric carbonate and preparation method thereof | |
CN114933516B (en) | Method for synthesizing deuterated compound in ionic liquid medium | |
Wu et al. | CuLi2Cl4 catalysed cross-coupling strategy for the formal synthesis of the diterpenoid (+)-subersic acid from (–)-sclareol | |
CN111018869B (en) | Preparation method of chiral fused ring pyrano-dihydropyrrole compound | |
CN115403519B (en) | Synthesis method of N-substituted isonicotinamide compound driven by visible light | |
CN117384177A (en) | Synthesis method of chiral pyrrole bridged ring compound | |
CN115477631B (en) | Synthesis method of compound containing dimethyl enol group | |
CN113896647B (en) | Synthesis method of tertiary amide | |
CN115304557B (en) | Enamine derivative and preparation method thereof | |
CN115477630B (en) | Coumarin derivatives and preparation method thereof | |
CN114907246B (en) | Total synthesis method of vitamin A, derivative thereof and deuterated compound thereof | |
CN110194760B (en) | Process for preparing 3-benzylidene-2- (7' -quinoline) -2, 3-dihydro-isoindol-1-ones |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination |